Zydus Cadila has received final USFDA approval to market minocycline hydrochloride extended release tablets used to treat acne. The company will market the drug in the strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg. It has also received tentative approval from the regulator for the tablets in 55 mg, 65 mg and 115 mg. The company will produce the drug at its formulations manufacturing facility in Moraiya in Ahmedabad. Minocycline hydrochloride extended release tablets are indicated to treat only inflammatory lesions of non-modular moderate to severe acne vulgaris in patients of 12 years of age or older.
Company Profile : Cadila Healthcare Ltd
Leave a Reply